. "* 2.13 +/- 0.71 mL/min/kg [patients had normal renal function (CrCl > 80 mL/min] * 68 +/- 8 mL/min/kg [CrCl was 50-80 mL/min] * 34 +/- 9 mL/min/kg [CrCl was 25-49 mL/min] * 20 +/- 4 mL/min/kg [CrCl was 10 - 24 mL/min]"@en . . . . . . . . "Phosphonomethanoic acid"@en . . . . . . . "63585-09-1"@en . . . . "Human Herpes Virus"@en . . . . . . "Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases."@en . . . "Oral, rat LD₅₀: >2,000 mg/kg. Signs of overdose include renal impairment."@en . . . "14-17%"@en . . . . . . . . . . "Foscarmet"@en . . "Phosphonoformate"@en . . "Charles E. McKenna, \"Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid.\" U.S. Patent US5072032, issued February, 1953."@en . . . . . . . "For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients."@en . "Poorly absorbed after oral administration (bioavailability from 12 to 22%)."@en . "Phosphonoformic acid"@en . " "@en . "Foscarnet"@en . " "@en . . . . . . . "approved"@en . "3.3-6.8 hours"@en . . "Foscarnet"@en . . "Carboxyphosphonic acid"@en . "An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. [PubChem]"@en . . .